drugset / Trial / NCT03051698

C1-inhibitor in Allergic ASThma Patients

NCT03051698

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this proof-of-concept study is to determine the effect of Intestinal Microbiota Depletion or Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients

Timeline

Start
2016-11-16
Primary completion
2019-10-23
Completion
2019-10-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CINRYZE Protein / enzyme biologic 100 iu/kg Intravenous
Subject Ciprofloxacin Small molecule
Subject Metronidazole Small molecule
Subject Vancomycin Other / unclassified

Indications